- Home
- NPCE vs SLP Comparison
NPCE vs SLP Comparison
Compare NPCE & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- SLP
- Stock Information
- Founded
- NPCE 1997
- SLP 1996
- Country
- NPCE United States
- SLP United States
- Employees
- NPCE N/A
- SLP N/A
- Industry
- NPCE Medical Specialities
- SLP EDP Services
- Sector
- NPCE Health Care
- SLP Technology
- Exchange
- NPCE Nasdaq
- SLP Nasdaq
- Market Cap
- NPCE 328.8M
- SLP 322.4M
- IPO Year
- NPCE 2021
- SLP 1997
- Fundamental
- Price
- NPCE $9.38
- SLP $17.00
- Analyst Decision
- NPCE Strong Buy
- SLP Buy
- Analyst Count
- NPCE 6
- SLP 8
- Target Price
- NPCE $16.67
- SLP $26.80
- AVG Volume (30 Days)
- NPCE 121.6K
- SLP 442.3K
- Earning Date
- NPCE 11-04-2025
- SLP 12-01-2025
- Dividend Yield
- NPCE N/A
- SLP N/A
- EPS Growth
- NPCE N/A
- SLP N/A
- EPS
- NPCE N/A
- SLP N/A
- Revenue
- NPCE $88,570,000.00
- SLP $80,383,000.00
- Revenue This Year
- NPCE $22.13
- SLP $12.65
- Revenue Next Year
- NPCE $6.07
- SLP $2.92
- P/E Ratio
- NPCE N/A
- SLP N/A
- Revenue Growth
- NPCE 23.32
- SLP 20.01
- 52 Week Low
- NPCE $6.03
- SLP $12.39
- 52 Week High
- NPCE $18.98
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- NPCE 35.09
- SLP 54.51
- Support Level
- NPCE $9.22
- SLP $17.28
- Resistance Level
- NPCE $10.81
- SLP $18.95
- Average True Range (ATR)
- NPCE 0.44
- SLP 0.89
- MACD
- NPCE -0.18
- SLP -0.03
- Stochastic Oscillator
- NPCE 6.09
- SLP 48.16
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.